exatecan mesylate
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Cervical Cancer
Conditions
Cervical Cancer
Trial Timeline
Jan 1, 2000 → Sep 1, 2003
NCT ID
NCT00004866About exatecan mesylate
exatecan mesylate is a phase 2 stage product being developed by Daiichi Sankyo for Cervical Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00004866. Target conditions include Cervical Cancer.
What happened to similar drugs?
8 of 20 similar drugs in Cervical Cancer were approved
Approved (8) Terminated (0) Active (12)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (11)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00055952 | Phase 2 | Completed |
| NCT00055939 | Phase 2 | Completed |
| NCT00017212 | Phase 2 | Completed |
| NCT00005938 | Phase 2 | Completed |
| NCT00004866 | Phase 2 | Completed |
| NCT00004108 | Phase 2 | Completed |
| NCT00004060 | Phase 2 | Completed |
| NCT00004046 | Phase 2 | Completed |
| NCT00003951 | Phase 2 | Completed |
| NCT00004045 | Phase 2 | Completed |
| NCT00004047 | Phase 1 | Completed |
Competing Products
20 competing products in Cervical Cancer